Diana F. Hausman - 02 Jul 2025 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 02 Jul 2025
Net transaction value: +$19,862
SEC form: 4
Accepted by SEC: 07 Jul 2025, 08:59:25 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Diana F. Hausman

Key filing fact

Diana F. Hausman filed Form 4 for Immuneering Corp (IMRX) on 07 Jul 2025.

Key facts

This page summarizes Diana F. Hausman's Form 4 filing for Immuneering Corp (IMRX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 07 Jul 2025, 08:59.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: +$19,862.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563992 Primary reporting owner

HAUSMAN DIANA

Relationship: Director
Address: 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Diana F. Hausman
Signature date: 07 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMRX transaction

Class A Common Stock

Purchase

Transaction value: $8,989
Shares: +2,500
Change %
Price: $3.60
Shares after: 2,500
Date: 02 Jul 2025
Ownership: Direct

IMRX transaction

Class A Common Stock

Purchase

Transaction value: $10,874
Shares: +3,000
Change %
Price: $3.62
Shares after: 3,000
Date: 02 Jul 2025
Ownership: By spouse

^* marks a reported price that did not pass the local price check.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .